Search Results
Results found for "Amgen"
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ : AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered and cancer, today announced that the companies have entered into a definitive agreement under which Amgen
- 📰 GPCR Weekly News, January 1 to 7, 2024
Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen
- 🤯Mind-blowing GPCR Scoops! Discover the Latest Breakthroughs! ⦿ Nov 18 - 24, 2024
GPCR News Let’s dive into the Classified GPCR News from November 18th to 24th, 2024 Industry News Amgen
- 📰 GPCR Weekly News, November 13 to 19, 2023
Abbreviated New Drug Application (ANDA) Litigation PostEra Announces a Research Collaboration with Amgen
- 📰 GPCR Weekly News, April 15 to 21, 2024
Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea Amgen
- 📰 GPCR Weekly News, October 30 to November 4, 2023
Inducted into RSC BMCS Hall of Fame and Receives Associated Medal in 2023 'This field is in its infancy': Amgen
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
Let’s dive into the Classified GPCR News from November 25th to December 1st, 2024 Industry News Amgen
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
can confirm the protein’s role in disease pathology and highlight allosteric sites that might be more amenable
